For instance, machine learning-powered predictive modelling tools can more accurately and quickly predict drug candidate behaviours and interactions, and maximise the potential for success in early discovery. Advanced machine learning (ML) algorithms are increasingly being used in the formulation design of biological drugs. By combining patterns from large data sets with knowledge from previous campaigns, resource requirements are minimised and development time scales are accelerated.

Quantum computing is a growing trend due to recent major advances in hardware making this technology a practically feasible thing. Some experts compare today's rapid progress in quantum computing with a similar period during the last century when personal computing was emerging through a cascade of technological advances both in hardware and software. To find our insights about the above questions and learn a thing or two about what the quantum computing industry looks like today, I sat down with Dr. Christopher Savoie, Co-founder, and CEO at Zapata Computing -- an American quantum software company on the cutting-edge of research in this area. Christopher is a scientist and a serial tech entrepreneur with 20 years of experience in the technology industry. He is the inventor of the Natural Language Understanding (NLU) technology behind Apple's Siri and he was recognized as a top business leader and innovator by Nikkei and MIT Technology Review.

The current wave of emerging digital technologies offers great opportunities to transform pharma operating models and improve the declining ROI on R&D productivity. Harnessing the power of digital technologies – such as robotic process automation, artificial intelligence, machine learning and organ-on-a-chip – can transform how clinical trials are conceived, designed and conducted. For instance, they can be used to automate processes, make efficient use of Big Data and support early decision-making with predictive analytics. The beginning of this digital transformation is well underway and is likely to accelerate. Therefore, harnessing these technologies will require a deep understanding of how they work, the role they will play in advancing clinical development and the limitations they present.

The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies. Among companies that adopt AI technology, 70 percent will obtain AI capabilities through cloud-based enterprise software, and 65 percent will create AI applications using cloud-based development services. In order to keep up with the changing competitive landscape and customer expectations, biopharma companies will need to accelerate their use of AI-enabled services. Biopharma organizations have started using scaled versions of AI over the last 1-2 years in some areas.

Specialty drugs account for just 2% of all medicines prescribed, yet they are on pace to comprise 50% of the drug spend in the next few years – ballooning to $400B in the US alone by 2020. Traditional approaches to drug utilization and cost management are simply not working. And biopharmaceutical pipelines are filled with new, high-priced, specialty drugs that continue to pressure health care budgets around the world. There is currently estimated to be up to $20billion in annual, solvable Specialty Rx inefficiencies in the US alone. By identifying which drugs are most effective for which patients (precision analytics for precision medicine) can a Decision support system (DSS) help solve the growing problem with Specialty Drug Use and Cost out of Control? This trend is unsustainable to the healthcare system.

For two decades, Arteric has led pharmaceutical and biotech brand teams through the selection and implementation of complex emerging marcom technologies. Scouting the digital landscape and educating clients are how Arteric helps marketing teams see opportunities that others miss and to transform those events into competitive advantage. Arteric's ongoing education program will continue on May 15 at the 2018 BioPharma eMarketing Summit West, where President and Chief Strategist Hans Kaspersetz will share two case studies during his presentation titled "AI - Super Hearing for Healthcare Marketers. BioPharma eMarketing Summit West is a TED-style venue that features an audience of more than 200 marketing executives from pharma, biotech, and medical device organizations. More than 45 thought leaders from companies such as Johnson and Johnson, Pfizer, Daiichi Sankyo, and Microsoft will share insights and case studies on leading-edge issues such as: · Utilizing big data to tell stories and to streamline pipelines · Establishing metrics to understand the effectiveness of a digital marketing strategy · Capitalizing on disruptive marketing "Detecting and capturing audience signals will be a central theme emphasized throughout several Biopharma eMarketing sessions," states Mr. Kaspersetz. "At the core of every Arteric digital strategy is the integration of the reality that customers are experiencing our brands across hundreds of micro-moments.

There's an old adage that goes, necessity is the mother of invention. This is certainly true in health care where market forces are spurring new innovations in biopharma. Recently, Deloitte published an analysis of some of the boldest breakthroughs likely to impact health care across the spectrum. In the Deloitte Center for Health Solutions' Top 10 health care innovations: Achieving more for less report, we surveyed leaders across the health care system on the innovations they believe will be transformative over the next decade. We define innovation as those activities or technologies that break performance constraints to attain a desired outcome in a way that genuinely pushes the envelope of change.